<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">ACAMPROSATE CALCIUM</span><br/>(a-cam-pro'sate)<br/><b>Classifications:</b> <span class="classification">central nervous system agent</span>; <span class="classification"> substance abuse deterrent</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>333 mg delayed-release tablets</p>
<h1><a name="action">Actions</a></h1>
<p>May interact with CNS glutamate and GABA neurotransmitter systems and help restore normal balance between neuronal excitation
         and inhibition. Acamprosate is a neurotransmitter analog.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Reduces craving for alcohol intake due to chronic use, but does not cause alcohol aversion or a disulfiram-like reaction as
         a result of ethanol ingestion.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Maintenance of abstinence from alcohol in patients with alcoholism</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to acamprosate calcium or any of its components; suicidal ideation; pregnancy (category C). Safety and efficacy
         in patients with severe renal impairment (Cl<sub>cr</sub> <img src="../images/special/approx.gif"/>30 mL/min) have not been established.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Moderate renal impairment; depression; lactation. Safety and efficacy of acamprosate have not been established in adolescents
         or children 
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">
<b>Maintenance of Alcohol Abstinence</b>
</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 666 mg t.i.d.<br/><br/><span class="indicationtitle">
<b>Renal Impairment</b>
</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> Cl<sub>cr</sub> 3050 mL/min: 333 mg t.i.d.; Cl<sub>cr</sub> </td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">
<b>Oral</b>
</span><br/><ul>
<li>Ensure that the drug is not chewed or crushed. It must be swallowed whole.</li>
<li>Store at 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Flu syndrome, chills. <span class="typehead">CNS:</span> Depression, anxiety, insomnia, asthenia, dizziness, paresthesia, headache, somnolence, decreased libido, amnesia, abnormal
      thinking, tremor. <span class="typehead">CV:</span> Palpitation, syncope. <span class="typehead">GI:</span>
<span class="speceff-common">Diarrhea</span>
<i>,</i> nausea, vomiting, anorexia, flatulence, dry mouth, abdominal pain, dyspepsia, constipation, increased appetite. <span class="typehead">Metabolic<b></b>
         			:</span> Peripheral edema, weight gain. <span class="typehead">Musculoskeletal<b></b>
         			:</span> Musculoskeletal pain. <span class="typehead"> Respiratory<b></b>
         			:</span> Rhinitis, cough, dyspnea, pharyngitis, bronchitis.  <span class="typehead">Skin<b></b>
         			:</span>  Pruritus, diaphoresis, rash. <span class="typehead"> Special Senses:</span> Abnormal vision, taste perversion. <span class="typehead">Urogenital<b></b>
         			:</span> Impotence. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>  None reported. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption<b></b>
         			:</span> 11% bioavailability. <span class="typehead">Metabolism<b></b>
         			:</span> Not metabolized. <span class="typehead">Elimination<b></b>
         			:</span> Renal. <span class="typehead">Half-Life:</span> 2033 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">
<b>Assessment &amp; Drug Effects</b>
</span></p>
<ul>
<li>Monitor for S&amp;S depression or suicidal thinking.</li>
<li>Monitor for dizziness or impaired judgment, thinking, and motor skills; take appropriate protective measures.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report any alcohol consumption while taking acamprosate.</li>
<li>Report promptly any of the following: unusual anxiousness or nervousness; depression or suicidal thoughts; burning or tingling
            sensations in arms, legs, hands, or feet; chest pains or palpitations; difficulty urinating.
         </li>
<li>Do not drive or engage in other hazardous activities until reaction to the drug is known.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>